Non Small Cell Lung CancerPhase 2NCT06514027
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
A Phase 2 study testing BEBT-109 Capsules, Pemetrexed Disodium for Injection and Carboplatin Injection in people with Non Small Cell Lung Cancer, run by BeBetter Med Inc at 1 site in China.
Trial summary
This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as first-line treatment for locally advanced, recurrent, or metastatic non-small cell lung cancer… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer
- What is being tested?
- BEBT-109 Capsules, Pemetrexed Disodium for Injection and Carboplatin Injection
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 28 Aug 2024to Nov 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants have a comprehensive understanding, voluntarily sign the Informed Consent Form (ICF), and are capable of completing all trial procedures;
- Age ≥18 years old, both males and females are eligible;
- According to the 8th edition of the American Joint Committee on Cancer（AJCC）TNM staging criteria for lung cancer: patients with histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) that is unresectable and intolerant or refuses radical synchronous radiochemotherapy, with locally advanced (stage IIIB or IIIC), recurrent, or metastatic (stage IV) disease;
- No prior systemic treatment for locally advanced (stage IIIB or IIIC) or recurrent/metastatic (stage IV) NSCLC. Note: 1) Neoadjuvant/adjuvant therapy is allowed as long as it has been completed at least 6 months before the disease is diagnosed as locally progressive or metastatic tumor; 2) Participants who have failed treatment with savolitinib in the past are allowed;
- EGFR exon 20 insertion mutations confirmed by peripheral blood or tumor tissue testing conducted by a tertiary hospital or a qualified third-party testing agency, and records must be provided. Patients may have only EGFR exon 20 insertion mutations or may also have other EGFR or HER2 mutations;
- At least one measurable lesion that meets the RECIST V1.1 criteria during the screening period. Lesions previously treated with radiotherapy cannot be used as target lesions unless there is clear radiological progression after radiotherapy;
Show all 16Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, and no decline in performance status within two weeks before the screening period, with an expected survival time ≥12 weeks;
- Provided that the subject has not received blood transfusion, erythropoietin, recombinant human thrombopoietin, or colony-stimulating factor treatment within 14 days before the screening period, laboratory tests indicate that the subject has adequate organ function, including:
- Absolute neutrophil count (ANC) ≥1.5×10^9/L; Platelet count (PLT) ≥100×10^9/L; Hemoglobin (HGB) ≥90 g/L;
- Total serum bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (for patients with Gilbert's syndrome, total bilirubin ≤3×ULN is allowed);
- AST and ALT ≤2.5×ULN (for those with liver metastasis, AST and ALT ≤5×ULN is allowed);
- Creatinine clearance ≥45 ml/min (calculated according to the Cockcroft-Gault formula), and urine protein ≤1+ or for subjects with urine protein ≥2+, the 24-hour urine protein total is ≤1 g/24 h;
- Activated partial thromboplastin time (APTT) ≤1.5×ULN, prothrombin time (PT) ≤1.5×ULN, international normalized ratio (INR) ≤1.5×ULN;
- Participants with a history of liver cirrhosis have a Child-Pugh score of A or B ≤7 at screening;
- The QT interval evaluated by ECG at screening is normal, defined as the corrected QT interval (Fridericia) (QTcF) ≤450 ms (for males) or ≤470 ms (for females) (those not meeting the standard need to be retested twice, and the average corrected value of the three measurements is taken);
- Male and female participants of childbearing potential must agree to use reliable contraceptive methods (hormonal or barrier methods) during the study period and for at least 6 months after the last administration of the drug, and must not breastfeed, with a negative blood pregnancy test before the first administration.
Who cannot join
- History of severe allergic diseases (such as uncontrollable asthma), severe drug (including investigational drugs not yet marketed) allergies, or known allergies or intolerance to any drug or drug component in this study;
- Diagnosis of other primary malignant tumors besides NSCLC, except for the following: non-melanoma skin cancer or cervical carcinoma in situ that has been adequately treated and cured, non-metastatic prostate cancer, or other primary malignant tumors that have been clearly recurrence-free for at least 3 years since the last treatment and have a low potential risk of recurrence;
- Major surgical procedures within 28 days before the first administration of the study drug, planned surgery during the study period, or postoperative complications from surgery performed within 2 months before the first administration of the study drug (except for minor surgeries that the investigator deems do not affect participation in the trial, such as catheter placement or minimally invasive biopsy);
- Presence of pleural effusion, ascites, or pericardial effusion with significant symptoms or requiring drainage;
- Poorly controlled diabetes mellitus. Definition: Hemoglobin A1C (HbA1c) ≥8%; or 7% ≤ Hemoglobin A1C < 8%, accompanied by clinical symptoms of diabetes, such as polyuria, polydipsia, polyphagia, and weight loss. (Subjects who have not been adequately treated to control blood sugar, after adjusting the drug treatment plan, with fasting blood glucose ≤10 mmol/L, and deemed suitable to participate in this study by the investigator, can be included);
- Received live vaccines within 28 days before the first administration of the study drug or plan to receive any live vaccines during the study period;
Show all 27Show fewer
- Subjects with a tendency to bleed or evidence of bleeding, including:
- History of active ulcers or perforations of the stomach and duodenum within 6 months before the first dose, persistent positive fecal occult blood, history of gastrointestinal bleeding such as ulcerative colitis;
- History of hemoptysis (defined as blood that is bright red or 2.5 ml) within 2 weeks before the first dose, or the presence of unhealed wounds, ulcers, or fractures;
- Vasculitis;
- Other conditions that may cause bleeding as determined by the investigator;
- Presence of severe gastrointestinal functional abnormalities that may affect the intake, transport, or absorption of the test drug (such as inability to swallow, uncontrollable vomiting, history of extensive gastrointestinal resection, chronic diarrhea, long-term use of proton pump inhibitors (PPIs) for gastric diseases, Crohn's disease, ulcerative colitis, intestinal obstruction, etc.);
- Presence of central nervous system (CNS) metastasis, except for those who are asymptomatic, have stable disease, and do not require drug treatment within 4 weeks before the start of the study treatment;
- Current spinal cord compression (symptomatic or asymptomatic, and detected by radiographic examination) or suspected meningeal disease (symptomatic or asymptomatic);
- Imaging (CT or MRI) shows that the tumor invades major blood vessels or is not clearly demarcated from major blood vessels;
- Significant clinical cardiovascular and cerebrovascular diseases within 6 months before the first study drug administration, including but not limited to:
- Acute myocardial infarction, unstable angina; f. New York Heart Association (NYHA) class III or IV congestive heart failure; g. Left ventricular ejection fraction <50% measured by echocardiography or multigated acquisition (MUGA) scan or with severe wall motion abnormalities; h. History of clinically significant ventricular arrhythmias (such as sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes); i. Subjects with poorly controlled hypertension, with systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg; j. Arterial/venous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism; low molecular weight heparin treatment is allowed, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or antiplatelet drugs (such as aspirin (>325 mg/day), clopidogrel (>75 mg/day), dipyridamole, ticlopidine, or cilostazol, etc.) is prohibited throughout the study period; k. Other arrhythmias deemed unsuitable for inclusion in this study by the investigator (such as third-degree atrioventricular block);
- Presence of other severe or uncontrolled diseases that the investigator deems unsuitable for participation in this clinical trial or may affect the subject's compliance with the study protocol, including but not limited to:
- Interstitial lung disease, radiation pneumonitis or drug-related pneumonitis requiring steroid treatment;
- History of uncontrolled hereditary or acquired thrombotic diseases;
- Persistent or active infections, including but not limited to: hepatitis B virus (meeting both hepatitis B surface antigen positive or hepatitis B e antigen positive, and HBV-DNA greater than the upper limit of normal of the center's laboratory), hepatitis C virus (meeting both HCV-Ab positive and HCV-RNA positive), human immunodeficiency virus (HIV-Ab positive), syphilis non-specific antibody positive (rapid plasma reagin [RPR] or toluidine red unheated serum test [TRUST]) without clinical symptoms, or other active infections that require systemic treatment within 14 days before the first study drug administration;
- Severe or unhealed wounds, ulcers, or fractures;
- History of drug or alcohol abuse or mental illness;
- Use of drugs or herbal supplements that are strong inhibitors or inducers of CYP 3A4 and CYP 2C8 within 14 days before the first administration of the study drug ;
- Received >30Gy of non-thoracic radical radiotherapy within 28 days before the first dose, >30Gy of thoracic radiotherapy within 24 weeks before the first dose, and ≤30Gy of palliative radiotherapy within 14 days before the first dose;
- Participation in another clinical trial and drug administration within 4 weeks before the first dose;
- Other conditions deemed unsuitable for entry into this study by the investigator.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060
Ju Yang, Master, +86-13408523335, ju.yang@bebettermed.com
About this study
Official title: A Multicenter, Open Phase II Clinical Study on the Safety and Efficacy of BEBT-109 Combined With Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as first-line treatment for locally advanced, recurrent, or metastatic non-small cell lung cancer carrying EGFR exon 20 insertion mutations.
Read the detailed description
This study initially sets up two cohorts. In cohort 1, the treatment is BEBT-109 combined with investigator-selected chemotherapy (injectable pemetrexed disodium combined with carboplatin or cisplatin injection). In cohort 2, the treatment is BEBT-109 monotherapy (BEBT-109 capsule at a dose of 180mg, taken orally once daily). Based on different dosing regimens of BEBT-109 capsules, cohort 1 is divided into three dose groups: A (BEBT-109 capsule at a dose of 180mg, taken orally once daily), B (BEBT-109 capsule at a dose of 120mg, taken orally twice daily), and C (BEBT-109 capsule at a dose of 120mg, taken orally once daily). Dose group A will first enroll six subjects to receive one cycle (a treatment cycle is 21 days) of drug treatment, and the safety data of subjects in dose group A will determine whether to adjust the dose for cohort 1 or to initiate other dose groups. If ≤2 subjects experience dose-limiting toxicity (DLT) during the DLT observation period, dose group A will be expanded to 20-30 subjects, and the decision to initiate dose group B will be made jointly by the investigators and the sponsor. If more than 2 subjects experience DLT, the decision to continue the study or to initiate dose group C will be made jointly by the investigators and the sponsor. Subjects in dose groups B and C will also initially enroll six subjects to undergo DLT safety follow-up, and then the decision to expand to 20-30 subjects will be made jointly by the investigators and the sponsor.
The decision to initiate cohort 2 will be based on the safety and efficacy results from cohort 1.
Each subject's study process includes three phases: screening, treatment, and follow-up. During the treatment period, subjects will undergo tumor assessments every 6 weeks ± 7 days. After discontinuing treatment, subjects will enter the follow-up period, where subjects without progressive disease (PD) will receive efficacy follow-up every 6 weeks ± 7 days (until tumor progression, death, or other antitumor treatment is initiated), and survival follow-up every 3 months (± 2 weeks). All subjects will receive study drug treatment until PD, death, intolerable toxicity occurs, or the subject withdraws informed consent (whichever occurs first).
- Conditions
- Non Small Cell Lung Cancer
- Being tested
- BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection
- Keywords
- BEBT-109, EGFR exon 20 insertion mutations, Drug combination, First-line treatment, Safety, Efficacy
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BEBT-109 CapsulesDrug
Also called KCBT-1083
BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
Pemetrexed Disodium for InjectionDrug
Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
Carboplatin InjectionDrug
Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Cisplatin InjectionDrug
Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
| Study group | Role | What they receive |
|---|---|---|
| Dose group A of BEBT-109 combined with investigator-selected chemotherapy | Experimental | BEBT-109 Capsules: Administration and Dosage: Oral administration, 180mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle.
Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. Receives: Drug: BEBT-109 Capsules; Drug: Pemetrexed Disodium for Injection; Drug: Carboplatin Injection; Drug: Cisplatin Injection |
| Dose group B of BEBT-109 combined with investigator-selected chemotherapy | Experimental | BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg; Frequency and Duration of Administration: Twice a day,and 21 days as a treatment cycle.
Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. Receives: Drug: BEBT-109 Capsules; Drug: Pemetrexed Disodium for Injection; Drug: Carboplatin Injection; Drug: Cisplatin Injection |
| Dose group C of BEBT-109 combined with investigator-selected chemotherapy | Experimental | BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle.
Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. Receives: Drug: BEBT-109 Capsules; Drug: Pemetrexed Disodium for Injection; Drug: Carboplatin Injection; Drug: Cisplatin Injection |
| BEBT-109 monotherapy | Experimental | BEBT-109 Capsules: Administration and Dosage: Oral administration, 180mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle. Receives: Drug: BEBT-109 Capsules |
What is being measured
The primary outcome is the main question the study is designed to answer.
ORR
Objective response rate
Measured: Every 6 weeks,assessed up to 24 months.
AE
Adverse event
Measured: From the first administration of the study drug to 28 days after the last administration of the study drug.
Secondary outcomes (1)
DCR
Disease control rate
Measured: Every 6 weeks,assessed up to 24 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2024
- Study start28 Aug 2024
- Primary completionJun 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This study initially sets up two cohorts. In cohort 1, the treatment is BEBT-109 combined with investigator-selected chemotherapy (injectable pemetrexed disodium combined with carboplatin or cisplatin injection). In cohort 2, the treatment is monotherapy with BEBT-109 (BEBT-109 capsule at a dose of 180mg, taken orally once daily). Based on different dosing regimens of BEBT-109 capsules, cohort 1 is divided into three dose groups: A (BEBT-109 capsule at a dose of 180mg, taken orally once daily), B (BEBT-109 capsule at a dose of 120mg, taken orally twice daily), and C (BEBT-109 capsule at a dose of 120mg, taken orally once daily). The decision to initiate cohort 2 will be based on the safety and efficacy results from cohort 1.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- BeBetter Med Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Li Zhang, Master, Principal investigator, Sun Yat-Sen University Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06514027
- Sponsor's protocol ID
- GBMT-109-P04
- Status last verified
- Aug 2026
- First submitted
- 17 Jul 2024
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Open Phase II Clinical Study on the Safety and Efficacy of BEBT-109 Combined With Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
- ClinicalTrials.gov ID
- NCT06514027
- Acronym / sponsor ID
- GBMT-109-P04
- Conditions
- Non Small Cell Lung Cancer
- Keywords
- BEBT-109, EGFR exon 20 insertion mutations, Drug combination, First-line treatment, Safety, Efficacy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- BeBetter Med IncIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2024 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 23 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as first-line treatment for locally advanced, recurrent, or metastatic non-small cell lung cancer carrying EGFR exon 20 insertion mutations.
Detailed description
This study initially sets up two cohorts. In cohort 1, the treatment is BEBT-109 combined with investigator-selected chemotherapy (injectable pemetrexed disodium combined with carboplatin or cisplatin injection). In cohort 2, the treatment is BEBT-109 monotherapy (BEBT-109 capsule at a dose of 180mg, taken orally once daily). Based on different dosing regimens of BEBT-109 capsules, cohort 1 is divided into three dose groups: A (BEBT-109 capsule at a dose of 180mg, taken orally once daily), B (BEBT-109 capsule at a dose of 120mg, taken orally twice daily), and C (BEBT-109 capsule at a dose of 120mg, taken orally once daily). Dose group A will first enroll six subjects to receive one cycle (a treatment cycle is 21 days) of drug treatment, and the safety data of subjects in dose group A will determine whether to adjust the dose for cohort 1 or to initiate other dose groups. If ≤2 subjects experience dose-limiting toxicity (DLT) during the DLT observation period, dose group A will be expanded to 20-30 subjects, and the decision to initiate dose group B will be made jointly by the investigators and the sponsor. If more than 2 subjects experience DLT, the decision to continue the study or to initiate dose group C will be made jointly by the investigators and the sponsor. Subjects in dose groups B and C will also initially enroll six subjects to undergo DLT safety follow-up, and then the decision to expand to 20-30 subjects will be made jointly by the investigators and the sponsor.
The decision to initiate cohort 2 will be based on the safety and efficacy results from cohort 1.
Each subject's study process includes three phases: screening, treatment, and follow-up. During the treatment period, subjects will undergo tumor assessments every 6 weeks ± 7 days. After discontinuing treatment, subjects will enter the follow-up period, where subjects without progressive disease (PD) will receive efficacy follow-up every 6 weeks ± 7 days (until tumor progression, death, or other antitumor treatment is initiated), and survival follow-up every 3 months (± 2 weeks). All subjects will receive study drug treatment until PD, death, intolerable toxicity occurs, or the subject withdraws informed consent (whichever occurs first).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- This study initially sets up two cohorts. In cohort 1, the treatment is BEBT-109 combined with investigator-selected chemotherapy (injectable pemetrexed disodium combined with carboplatin or cisplatin injection). In cohort 2, the treatment is monotherapy with BEBT-109 (BEBT-109 capsule at a dose of 180mg, taken orally once daily). Based on different dosing regimens of BEBT-109 capsules, cohort 1 is divided into three dose groups: A (BEBT-109 capsule at a dose of 180mg, taken orally once daily), B (BEBT-109 capsule at a dose of 120mg, taken orally twice daily), and C (BEBT-109 capsule at a dose of 120mg, taken orally once daily). The decision to initiate cohort 2 will be based on the safety and efficacy results from cohort 1.
| Arm | Type | Receives |
|---|---|---|
| Dose group A of BEBT-109 combined with investigator-selected chemotherapy | Experimental | Drug: BEBT-109 Capsules, Drug: Pemetrexed Disodium for Injection, Drug: Carboplatin Injection, Drug: Cisplatin InjectionBEBT-109 Capsules: Administration and Dosage: Oral administration, 180mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle. Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle. Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. |
| Dose group B of BEBT-109 combined with investigator-selected chemotherapy | Experimental | Drug: BEBT-109 Capsules, Drug: Pemetrexed Disodium for Injection, Drug: Carboplatin Injection, Drug: Cisplatin InjectionBEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg; Frequency and Duration of Administration: Twice a day,and 21 days as a treatment cycle. Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle. Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. |
| Dose group C of BEBT-109 combined with investigator-selected chemotherapy | Experimental | Drug: BEBT-109 Capsules, Drug: Pemetrexed Disodium for Injection, Drug: Carboplatin Injection, Drug: Cisplatin InjectionBEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle. Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle. Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. |
| BEBT-109 monotherapy | Experimental | Drug: BEBT-109 CapsulesBEBT-109 Capsules: Administration and Dosage: Oral administration, 180mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Participants have a comprehensive understanding, voluntarily sign the Informed Consent Form (ICF), and are capable of completing all trial procedures;
- Age ≥18 years old, both males and females are eligible;
- According to the 8th edition of the American Joint Committee on Cancer（AJCC）TNM staging criteria for lung cancer: patients with histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) that is unresectable and intolerant or refuses radical synchronous radiochemotherapy, with locally advanced (stage IIIB or IIIC), recurrent, or metastatic (stage IV) disease;
- No prior systemic treatment for locally advanced (stage IIIB or IIIC) or recurrent/metastatic (stage IV) NSCLC. Note: 1) Neoadjuvant/adjuvant therapy is allowed as long as it has been completed at least 6 months before the disease is diagnosed as locally progressive or metastatic tumor; 2) Participants who have failed treatment with savolitinib in the past are allowed;
- EGFR exon 20 insertion mutations confirmed by peripheral blood or tumor tissue testing conducted by a tertiary hospital or a qualified third-party testing agency, and records must be provided. Patients may have only EGFR exon 20 insertion mutations or may also have other EGFR or HER2 mutations;
Key exclusion criteria (27 listed)
- History of severe allergic diseases (such as uncontrollable asthma), severe drug (including investigational drugs not yet marketed) allergies, or known allergies or intolerance to any drug or drug component in this study;
- Diagnosis of other primary malignant tumors besides NSCLC, except for the following: non-melanoma skin cancer or cervical carcinoma in situ that has been adequately treated and cured, non-metastatic prostate cancer, or other primary malignant tumors that have been clearly recurrence-free for at least 3 years since the last treatment and have a low potential risk of recurrence;
- Major surgical procedures within 28 days before the first administration of the study drug, planned surgery during the study period, or postoperative complications from surgery performed within 2 months before the first administration of the study drug (except for minor surgeries that the investigator deems do not affect participation in the trial, such as catheter placement or minimally invasive biopsy);
- Presence of pleural effusion, ascites, or pericardial effusion with significant symptoms or requiring drainage;
- Poorly controlled diabetes mellitus. Definition: Hemoglobin A1C (HbA1c) ≥8%; or 7% ≤ Hemoglobin A1C < 8%, accompanied by clinical symptoms of diabetes, such as polyuria, polydipsia, polyphagia, and weight loss. (Subjects who have not been adequately treated to control blood sugar, after adjusting the drug treatment plan, with fasting blood glucose ≤10 mmol/L, and deemed suitable to participate in this study by the investigator, can be included);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BEBT-109 CapsulesAlso: KCBT-1083BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle. | Drug | BEBT-109 monotherapy, Dose group A of BEBT-109 combined with investigator-selected chemotherapy, Dose group B of BEBT-109 combined with investigator-selected chemotherapy, Dose group C of BEBT-109 combined with investigator-selected chemotherapy |
| Pemetrexed Disodium for InjectionPemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle. | Drug | Dose group A of BEBT-109 combined with investigator-selected chemotherapy, Dose group B of BEBT-109 combined with investigator-selected chemotherapy, Dose group C of BEBT-109 combined with investigator-selected chemotherapy |
| Carboplatin InjectionCarboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. | Drug | Dose group A of BEBT-109 combined with investigator-selected chemotherapy, Dose group B of BEBT-109 combined with investigator-selected chemotherapy, Dose group C of BEBT-109 combined with investigator-selected chemotherapy |
| Cisplatin InjectionCisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles. | Drug | Dose group A of BEBT-109 combined with investigator-selected chemotherapy, Dose group B of BEBT-109 combined with investigator-selected chemotherapy, Dose group C of BEBT-109 combined with investigator-selected chemotherapy |
Primary outcome
ORR
Time frame: Every 6 weeks,assessed up to 24 months.
Objective response rate
AE
Time frame: From the first administration of the study drug to 28 days after the last administration of the study drug.
Adverse event
1 secondary outcome
DCR
Time frame: Every 6 weeks,assessed up to 24 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Li Zhang, Master principal investigator
Sun Yat-Sen University Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing BEBT-109 Capsules, Pemetrexed Disodium for Injection and Carboplatin Injection in people with Non Small Cell Lung Cancer, run by BeBetter Med Inc at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kegang Jiang, Master (+86-18664786382, kjiang@bebettermed.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ORR (time frame: Every 6 weeks,assessed up to 24 months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.